Atai Life Sciences N.V. [ATAI] stock for 97,801 USD was acquired by Apeiron Investment Group Ltd.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Atai Life Sciences N.V. shares valued at $97,801 were purchased by Apeiron Investment Group Ltd. on Apr 29. At $4.47 per share, Apeiron Investment Group Ltd. acquired 21,900 shares. The insider’s holdings grew to 1,799,302 shares worth approximately $6.19 million following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Also, Apeiron Investment Group Ltd. purchased 34,700 shares, netting a total of over 154,689 in proceeds. Following the buying of shares at $4.46 each, the insider now holds 1,777,402 shares.

Before that, Apeiron Investment Group Ltd. had added 19,803 shares to its account. In a trade valued at $91,939, the 10% Owner bought Atai Life Sciences N.V. shares for $4.64 each. Upon closing the transaction, the insider’s holdings increased to 19,803 shares, worth approximately $5.99 million.

As published in their initiating research note from Maxim Group on November 30, 2021, Atai Life Sciences N.V. [ATAI] has been a Buy and the price target has been revised to $25. This represents a 86.24% premium over Wednesday’s closing price. Analysts at ROTH Capital started covering the stock with ‘”a Buy”‘ outlook in a report released in mid November. As of October 18, 2021, H.C. Wainwright has initiated its “Buy” rating for ATAI. Earlier on September 01, 2021, Jefferies initiated its rating. Their recommendation was “a Buy” for ATAI stock.

Analyzing ATAI’s Price Performance

On Wednesday, Atai Life Sciences N.V. [NASDAQ: ATAI] plunged -6.27% to $3.44. The stock’s lowest price that day was $3.38, but it reached a high of $3.70 in the same session. During the last five days, there has been a drop of approximately -14.00%. Over the course of the year, Atai Life Sciences N.V. shares have dropped approximately -54.91%. Shares of the company reached a 52-week high of $7.98 on 01/03/22 and a 52-week low of $2.95 on 06/14/22. A 50-day SMA is recorded $4.23, while a 200-day SMA reached $5.03. Nevertheless, trading volume fell to 1.01 million shares from 0.6 million shares the previous day.

Support And Resistance Levels for Atai Life Sciences N.V. (ATAI)

According to the 24-hour chart, there is a support level at 3.31, which, if violated, would cause prices to drop to 3.19. In the upper region, resistance lies at 3.63. The next price resistance is at 3.83. RSI (Relative Strength Index) is 31.74 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.47, which suggests the price will decrease in the coming days. Percent R is at 94.74%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Atai Life Sciences N.V. subject to short interest?

Stocks of Atai Life Sciences N.V. saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.76 million shares to 5.14 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 4.38 million shares. A jump of 14.79% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.86 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.86.

Which companies own the most shares of Atai Life Sciences N.V. (ATAI)?

According to Alpha Wave Global LP filings, the company currently owns 2,134,625 shares, which is about 1.33% of the total ATAI shares outstanding. With the completion of the sale transaction, ARK Investment Management LLC’s stake is now worth $7,285,658. Morgan Stanley Investment Managem acquire a 15.54% interest valued at $6.72 million while BMO Asset Management Corp. 1,474,889 stake. In its current portfolio, BlackRock Fund Advisors holds 1,097,679 shares valued at $4.94 million.

In terms of Atai Life Sciences N.V. share price expectations, FactSet research, analysts set an average price target of $23.78 in the next 12 months, up nearly 499.46% from the previous closing price of $3.67. Analysts anticipate Atai Life Sciences N.V. stock to reach $50.00 by 2022, with the lowest price target being $6.60. In spite of this, 12 analysts ranked Atai Life Sciences N.V. stock as a Buy at the end of 2022. On July 13, 2021, RBC Capital Mkts assigned a price target of “a Sector perform” to the stock and initiated coverage with a $19.

LEAVE A REPLY

Please enter your comment!
Please enter your name here